AVEO Pharmaceuticals, Inc. (AVEO) Could Be A Humongous Winner

Analysts at B. Riley FBR cut their rating on shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) from Buy to Neutral in their opinion released on February 04. H.C. Wainwright analysts have downgraded their rating of AVEO stock from Buy to Neutral in a separate flash note to investors on February 01.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) short sellers believe it will rise in price. The most recent short interest data has been released for the January 31st settlement date, which shows a -416,999 share decrease in total short interest for AVEO, to 15,065,912, a retreat of 2.69% since January 15th. Average daily volume for AVEO Pharmaceuticals, Inc. at the January 31st settlement jumped to 3,447,667, as compared to 1,287,168 at the January 15th report. That brought days to cover to 4.369886, a 63.67% decrease from the 12.02866 days to cover recorded at the prior short interest data release. You could look at analyst ratings. The average analyst recommendations at 1.8 suggests selling these shares. But the opinions of a small number of people, though sometimes influential, doesn’t always speak for the hundreds of thousands of traders on Wall Street.

By watching the trading activity of corporate insiders, it will become easier to get a sense of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)’s prospects. The earliest insider trade took place on 12/21/2018. Growth Equity Opportunities Iv gathered a total of 500 thousand shares of company at average share price of $1.55. The total for the purchase was set at $775 thousand. After this transaction, the 10% Owner account balance stood at 20.9 million shares. The stock lost -61.94 percent since that insider purchase. On 12/21/2018, Barris Peter J, 10% Owner, purchased 500 thousand shares at a price per share of $1.55. This added 775 thousand shares to the insider’s fortune and the stock saw a -61.94 percent retreat in value since the news became public. This transaction left 20.9 million shares in the 10% Owner account. On 12/21/2018, 10% Owner Baskett Forest performed a purchase transaction worth $775 thousand. This purchase at $1.55 each has added 500 thousand shares into the insider’s portfolio position. Meanwhile, shares have recorded -61.94 percent decrease since the transaction was reported. The insider now is left with 20.9 million shares remaining in the account. Florence Anthony A. Jr., who performs the 10% Owner job, bought 500 thousand shares for $775 thousand. The acquisition occurred on 12/21/2018 was priced at $1.55 per share. The share price plunged -61.94 percent since the reporting date. Florence Anthony A. Jr. now left with a stake of 20.9 million AVEO stock worth $12.33 million after the insider buying.

AVEO Pharmaceuticals, Inc. (AVEO) is expected to jump by 747.46 percent over the next 12 months, according to price target estimates compiled by finviz. Meanwhile, they have set a $3 price as 12-month high target. This represents a whopping 408.47 percent increase from where shares are trading today. The 12-month median price target assigned by the analysts stands at $2, which represents a return potential of 238.98 percent when compared to the closing price of the stock of $0.59 on Monday, February 11. The lowest price target for the stock is $1 — slightly more than 69.49 percent from AVEO’s current share price.

The shares are currently floating around the first support level of $0.58. Below this, the next support is placed in the zone of $0.56. Till the time, the AVEO stock trades above this level, bulls have nothing to fear. On momentum oscillators front, ‘RSI’ has touched 19.1 on daily chart, which may remain a cause for comfort. If the price breaks below $0.56 level on closing basis, then we may see more profit booking and the stock may show further weakness. On the flipside, hitting the $0.6 mark may result into a pull-back move towards $0.6 level.

AVEO shares dropped 0 points or -0.66 percent on Monday to $0.59 with a light trade volume of 2.605 million shares. After opening the session at $0.5876, the shares went as high as $0.591 and as low as $0.57, the range within which the stock’s price traded throughout the day. The firm is left with a market cap of $73.51 million and now has 125.42 million shares outstanding. AVEO Pharmaceuticals, Inc. (AVEO) stock has lost -71.55 percent of market value in 21 trading days.

AVEO stock has a trailing 3-year beta of 1.22, offering the possibility of a higher rate of return, but also posing more risk. The portion of a company’s profit allocated to each outstanding share of common stock was -$0.2 a share in the trailing twelve months. The stock’s value has fallen -63.37 percent year to date (YTD) against a decline of -80.78 percent in 12 month’s time. The company’s shares still trade -83.67 percent away from its 1-year high of $3.59 and 4.1 percent up from 52-week low of $0.56. The average consensus rating on the company is 1.8, on a scale where 5 equates to a unanimous sell rating. In short, the mean analyst recommendations are calling this stock a buy.

Shares of AVEO Pharmaceuticals, Inc. (AVEO) are trading at a P/E ratio of 0 times earnings reported for the past 12 months. The industry AVEO operates in has an average P/E of 87.64. Its P/E ratio went as low as 0X and as high as 0 over the 5-year span. Further, it is sporting a 18.38 on the Price-to-Sales ratio. Compare this with the industry average P/S of 51.22. 0 percent is the gross profit margin for AVEO Pharmaceuticals, Inc. and operating margin sits at 0 percent. Along with this, the net profit margin is 0 percent.

AVEO will be showing off its Q4 earnings on March 12. Analysts are forecasting revenue to climb 2826.8 percent to $2.4M in the next fiscal quarter, while earnings are seen soaring by nearly -300 percent to -$0.06 per share. History has shown that shares in AVEO Pharmaceuticals, Inc. have gone down on 19 different earnings reaction days and are predicted to add 0.05 percent when the company reports upcoming earnings. In last reported earnings results, it earned -$0.18 per share, worse than the -$0.06, adjusted, expected by Thomson Reuters consensus estimate. Revenue was $2.47M, better than the $680000 analysts expected. Earnings are estimated to increase by -58.1 percent this year, -14.3 percent next year and continue to increase by 0 percent annually for the next 5 years.